Edwards Lifesciences Corporation revised earnings guidance for the full year 2024. For the year, the company now expects full-year 2024 sales growth to be at the high end of the prior guidance of 8% to 10% and $6.3 billion to $6.6 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.09 USD | -0.19% | -1.00% | +11.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.59% | 51.37B | |
+8.06% | 218B | |
+6.94% | 184B | |
+13.54% | 135B | |
-0.27% | 62.38B | |
+7.76% | 50.9B | |
+1.14% | 40.87B | |
+3.21% | 36.28B | |
+26.11% | 31.88B | |
+17.81% | 24.39B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024